This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Scott P Turner: Innovator in Cancer Biomarkers
Introduction
Scott P Turner is a notable inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of cancer research through his innovative patent. His work focuses on improving the understanding of tumor biology and enhancing treatment strategies for cancer patients.
Latest Patents
Scott P Turner holds a patent for an "Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue." This patent describes an IHC assay designed to detect and quantify spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue. The assay aims to generate proximity biomarkers that predict which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. Additionally, the patent outlines methods for testing tumor samples for these proximity biomarkers and for treating subjects with a PD-1 antagonist based on the test results. Scott has 1 patent to his name.
Career Highlights
Scott P Turner is currently employed at Merck Sharp & Dohme Corp., where he continues to advance his research in cancer treatment. His work has the potential to significantly impact patient outcomes and treatment efficacy.
Collaborations
Scott has collaborated with notable colleagues, including Jennifer H Yearley and Belma Dogdas. These collaborations enhance the research environment and contribute to the development of innovative solutions in cancer therapy.
Conclusion
Scott P Turner is a dedicated inventor whose work in cancer biomarkers is paving the way for more effective treatments. His innovative patent and ongoing research efforts are crucial in the fight against cancer.